Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Citius OncologyCTOR -0.99%10 EV-to-EBIT is -1.55 as of Jul. 16, 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 687 Drug Manufacturers companies, Citius Oncology ranks worse than 145560.26% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Citius Oncology's Enterprise Value for the quarter that ended in Mar. 2026 was $58.81 Mil.
Citius Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Oncology EV-to-EBIT Related Terms
Citius Oncology EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Citius Oncology's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Citius Oncology's EV-to-EBIT falls into.
Citius Oncology's current Enterprise Value is $64.58 Mil.
Citius Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Oncology (CTOR) has a EV-to-EBIT of -1.55 as of Jul. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Citius Oncology and its competitors. According to the industry distribution chart, Citius Oncology ranks #999999 out of 687 companies in the Drug Manufacturers industry.
Is Citius Oncology's EV-to-EBIT too high?
Citius Oncology's current EV-to-EBIT is -1.55. Based on the distribution chart, Citius Oncology ranks #999999 out of 687 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's EV-to-EBIT compare to INCR and TLPH?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #999999 out of 687 companies for EV-to-EBIT. This places Citius Oncology in the lower half of its industry. The industry median EV-to-EBIT is 15.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current EV-to-EBIT is -1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current EV-to-EBIT of -1.55. The current EV-to-EBIT is -1.55. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Citius Oncology (CTOR), the current EV-to-EBIT is -1.55 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
